title: Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.
abstract: The use of drug-eluting stents (DESs) dramatically reduced in-stent restenosis. However, the increasing use of these stents has raised concern about their potential thrombogenicity. Indeed, the particularity of DES thrombosis compared with bare metal stent thrombosis is a high rate of late thrombosis. Antiplatelet therapy is efficient in preventing DES thrombosis. However, this therapy could be optimized and may be improved in the future. This article will review the mechanisms and the epidemiology of stent thrombosis. Then, we will summarize the antiplatelet therapeutic strategies used to prevent stent thrombosis and especially DES-associated thrombosis. Finally, we will present some data with regard to potential advantages and pitfalls in DES thrombosis prevention using novel antiplatelet agents currently under development, as well as future stent designs with improved healing properties.
authors.affiliation: Université de Montréal, Institut de Cardiologie de Montréal, Research Centre, Department of Medicine, 5000, rue Bélanger, Montréal, Qc H1T 1C8, Canada.
authors.forename: Gregory
authors.initials: G
authors.lastname: Ducrocq
authors.forename: Victor
authors.initials: V
authors.lastname: Serebruany
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Tanguay
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation; D000818:Animals; D003324:Coronary Artery Disease / Q000628:therapy; D023903:Coronary Restenosis / Q000517:prevention & control; D003328:Coronary Thrombosis / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D054855:Drug-Eluting Stents / Q000009:adverse effects; D004867:Equipment Design; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors